AI Article Synopsis

  • - This study evaluated how early metabolic responses (ΔSUV) after two weeks of cetuximab treatment can predict clinical outcomes in patients with RAS-wildtype metastatic colorectal cancer (mCRC).
  • - A total of 40 patients participated, with results showing that those who responded to treatment had a significantly higher ΔSUV, indicating a clear link between metabolic response and early clinical response.
  • - The findings suggest that ΔSUV could be an important indicator of survival rates, with a median progression-free survival of 11.7 months and overall survival of 33.5 months, but further validation with larger groups is needed.

Article Abstract

Background: To assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC).

Methods: In this prospective phase II study, RAS-wt mCRC pts received a single-agent cetuximab run-in therapy of 2 weeks. ΔSUV was assessed with FDG-PET/CT on days 0 and 14. Early clinical response (ECR) was evaluated with CT on day 56 after treatment with FOLFIRI-cetuximab. Primary endpoint was the predictive significance of ΔSUV for ECR. Secondary endpoints were PFS (progression free survival), OS and the influence of ΔSUV on survival.

Results: Forty pts were enroled and 33 pts were evaluable for the primary endpoint. The CT response rate was 57.6%. For responders, ΔSUV was significantly higher (p = 0.0092). A significant association of ΔSUV with ECR was found (p = 0.02). Median PFS was 11.7 months and median OS was 33.5 months with a 1-year survival rate of 87.9%. ΔSUV was found to significantly impact the hazard for OS (p = 0.045).

Conclusions: We demonstrate that cetuximab induces metabolic responses in mCRC pts. The study endpoint was met with the ΔSUV discriminating between responders and non-responders. However, these data should be validated in larger patient cohorts.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048023PMC
http://dx.doi.org/10.1038/s41416-018-0152-4DOI Listing

Publication Analysis

Top Keywords

early metabolic
8
metabolic response
8
clinical response
8
metastatic colorectal
8
colorectal cancer
8
Δsuv
8
mcrc pts
8
primary endpoint
8
Δsuv ecr
8
response
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!